glp 1 gip gcg Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes - Xu - 2025 - Diabetes, Obesity and Metabolism Neurotrophic and neuroprotective effects of

Semaglutide (Ozempic/Wegovy) legal status Current legal status: FDA-approved for diabetes and obesity Completely legal with prescription Illegal to possess without prescription Not a controlled substance (no DEA scheduling) Prescription pathways: Traditional doctor visit (endocrinologist, primary care) Telehealth prescription services (Ro, Calibrate, Found, etc.) Compounded semaglutide from licensed compounding pharmacies Research chemical semaglutide: Some companies sell non-FDA-approved semaglutide as research chemical Legal gray area similar to BPC-157 Quality and purity concerns (no FDA oversight) Prescription versions are safer and more reliable See our semaglutide vs tirzepatide guide for prescription options

Claudia von Boeselager [00:58:57]: Thank you for coming today

They are different molecules with different mechanisms, different efficacy profiles, and different regulatory statuses

10.1046/j.1365-313x.2000.00911.x Plant J

10.1124/jpet.106.103572 20 BertilssonG.PatroneC.ZachrissonO.AnderssonA.DannaeusK.HeidrichJ.et al

Active Ingredients:Reduced Glutathione...... 500mg,Alpha Lipoic Acid. 500mg,Sodium Ascorbate............. 100mg,Vitamin E 400IU,Vitamin B6......1.3mg